Sabatini Brent 4

What Happened Brent Sabatini, SVP and Chief Accounting Officer of Vir Biotechnology (VIR), reported a sale of 7,711 shares on 2026-03-23 at $9.12 per share, for total proceeds of approximately $70,324. The transaction is reported as a sale (code S).

Key Details

• Transaction date: 2026-03-23; Filing date: 2026-03-24 (Form 4 accession 0001628280-26-020823).
• Price and amount: 7,711 shares sold at $9.12 each; proceeds ≈ $70,324.
• Reported as an open-market or private sale (S).
• Footnote: Sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2025.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No indication in the provided data that the filing was late.

Context Sales reported under a pre-established Rule 10b5-1 plan are typically scheduled trades and do not, by themselves, indicate a change in the insider’s view of the company. For retail investors, purchases are generally more informative about insider confidence; routine sales like this can reflect diversification or liquidity needs rather than a negative signal.